Abstract
Aim Biochemical markers, including microRNAs (miRs), may facilitate the diagnosis and prognosis of breast cancer. This study was aimed at assessing serum miR-155 expression in patients with breast cancer and receptors. Methods This case-control study was conducted on 36 patients with breast cancer and 36 healthy individuals. After RNA extraction from the patient's serum, cDNA was synthesized. The expression of miR-155 was measured using RT-qPCR. Demographic and histochemical data were extracted from patient documents. Data were analyzed using the Statistical Package for the Social Sciences (SPSS) software. Results The mean age of subjects in breast cancer and control groups was 47.64 ± 8.19 and 47.36 ± 7.52 years, respectively. The serum miR-155 expression was higher in the cancer group (1.68 ± 0.66) compared to the control group (p < 0.0001). There was a significant relationship between serum miR-155 expression and the tumor grade (p < 0.001), tumor stage (p < 0.001), and tumor size (p < 0.001) of the patients. However, no relationship between miR-155 expression and the presence of lymph node involvement (p = 0.15), HER2 (p = 0.79), Ki-67 (p = 0.9), progesterone receptor (p = 0.54), and estrogen receptors (p = 0.84) was found. The ROC curve analysis showed that the AUC was 0.89 (77.78% sensitivity and 88.89% specificity), and the cutoff was 1.4 (Youden index: 0.6667) for detecting breast cancer. Conclusion The findings of this study revealed that serum miR-155 may serve as a potential noninvasive molecular biomarker for breast cancer diagnosis and can help predict the grade of the disease.
Highlights
Breast cancer (BC) is the most prevalent cancer worldwide and accounts for 22.8% of female cancers [1]
One of the goals of this study is to investigate the role of miR-155 in women with breast cancer, but its primary goal is to find a biomarker for breast cancer diagnosis based on hormonal receptors
There were no significant difference between the breast cancer and control groups in terms of age (p = 0:881), body mass index (BMI) (p = 0:186), number of pregnancies (p = 0:810), age of menarche (p = 0:306), history of abortion (p = 0:635), and contraceptive drug usage (p = 0:475)
Summary
Breast cancer (BC) is the most prevalent cancer worldwide and accounts for 22.8% of female cancers [1]. Breast cancer mortality was estimated to be 626679 in 2018 [2]. In Iran, breast cancer accounts for 76% of female cancers, with 8500 new cases each year [3]. The most important risk factors for breast cancer include female gender, age (30 years old and older) [4], positive family history for breast cancer [4], and familial genetic mutations, including mutations in the breast cancer A1 (BRCA1) and BRCA2 genes [5]. A positive history for cancer in the endometrium, ovaries, or colon, as well as radiation therapy for Hodgkin’s lymphoma, was shown to increase the risk of breast cancer [6].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
